Topics: Health Care, Health Service

  • Nordic Drugs Announces CE Mark Approval for Lacrifill® Canalicular Gel, Introducing a New Treatment Option for Dry Eye in the Nordic Region

    Nordic Drugs Announces CE Mark Approval for Lacrifill® Canalicular Gel, Introducing a New Treatment Option for Dry Eye in the Nordic Region

    Malmö, Sweden – 14th of April 2025 – Nordic Drugs today announces that Lacrifill®, a novel therapy for the treatment of dry eye disease, has received CE mark approval. This regulatory milestone, achieved several months ahead of schedule, paves the way for market introduction across the Nordic region and other European countries in the coming months.
    Lacrifill® is a cross-linked hyaluronic acid

  • Teysuno korvattavaksi metastaattisen kolorektaalisyövän hoidossa

    Teysuno korvattavaksi metastaattisen kolorektaalisyövän hoidossa

    Teysuno®-valmisteelle on myönnetty Suomessa korvattavuus metastaattisen kolorektaalisyövän hoidossa 1.5.2023 lähtien. Peruskorvausoikeus myönnetään etäpesäkkeisen kolorektaalisyövän hoitoon monoterapiana tai yhdistelmänä oksaliplatiinin tai irinotekaanin kanssa, joko ilman bevasitsumabia tai bevasitsumabin kanssa, kun hoidon jatkaminen muulla fluoropyrimidiinillä ei ole mahdollista taudin aiemman

Enter your email address to follow Nordic Drugs

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Nordic Drugs.

Okay